Erkurt M.A.Berber I.Tekgündüz E.Dogu M.H.Korkmaz S.Demir C.Yilmaz M.Akay O.M.Pala C.Bilen Y.Kaya E.Sari I.Sencan M.Kuku I.Altuntaş F.Dal M.S.Aydogdu I.2025-04-102025-04-102016http://hdl.handle.net/20.500.14701/48748We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.Article10.1016/j.transci.2016.01.018